Terns Pharmaceuticals Inc (NASDAQ: TERN) is 3.79% higher on its value in year-to-date trading and has touched a low of $4.32 and a high of $11.40 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The TERN stock was last observed hovering at around $5.67 in the last trading session, with the day’s gains setting it 0.08%.
Currently trading at $5.75, the stock is -7.13% and -10.40% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.93 million and changing 1.41% at the moment leaves the stock -17.74% off its SMA200. TERN registered -8.59% loss for a year compared to 6-month loss of -15.57%. The firm has a 50-day simple moving average (SMA 50) of $6.4174 and a 200-day simple moving average (SMA200) of $6.989725.
The stock witnessed a -9.59% gain in the last 1 month and extending the period to 3 months gives it a -29.88%, and is -2.21% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.08% over the week and 7.18% over the month.
Terns Pharmaceuticals Inc (TERN) has around 66 employees, a market worth around $495.29M and $0.00M in sales. Distance from 52-week low is 33.10% and -49.56% from its 52-week high. The company has generated returns on investments over the last 12 months (-24.10%).
The EPS is expected to grow by 6.25% this year.
Terns Pharmaceuticals Inc (TERN) Top Institutional Holders
208.0 institutions hold shares in Terns Pharmaceuticals Inc (TERN), with institutional investors hold 97.92% of the company’s shares. The shares outstanding are 84.92M, and float is at 62.29M with Short Float at 9.96%. Institutions hold 97.77% of the Float.
The top institutional shareholder in the company is ORBIMED ADVISORS LLC with over 7.62 million shares valued at $51.89 million. The investor’s holdings represent 10.2326% of the TERN Shares outstanding. As of 2024-06-30, the second largest holder is VIVO CAPITAL, LLC with 6.18 million shares valued at $42.11 million to account for 8.3038 of the shares outstanding. The other top investors are DEEP TRACK CAPITAL, LP which holds 6.1 million shares representing 8.1923% and valued at over $41.54 million, while SOLEUS CAPITAL MANAGEMENT, L.P. holds 6.6448 of the shares totaling 4.95 million with a market value of $33.69 million.
Terns Pharmaceuticals Inc (TERN) Insider Activity
The most recent transaction is an insider purchase by Burroughs Amy L., the company’s Chief Executive Officer. SEC filings show that Burroughs Amy L. bought 15,450 shares of the company’s common stock on Dec 05 ’24 at a price of $7.15 per share for a total of $0.11 million. Following the purchase, the insider now owns 19099.0 shares.
Terns Pharmaceuticals Inc disclosed in a document filed with the SEC on Sep 12 ’24 that Lu Hongbo (Director) bought a total of 476,190 shares of the company’s common stock. The trade occurred on Sep 12 ’24 and was made at $10.50 per share for $5.0 million. Following the transaction, the insider now directly holds 0.48 million shares of the TERN stock.
Still, SEC filings show that on Sep 10 ’24, Vignola Mark J. (Chief Financial Officer) disposed off 10,000 shares at an average price of $11.00 for $0.11 million. The insider now directly holds 91,940 shares of Terns Pharmaceuticals Inc (TERN).
